A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.
Watanabe K, Otsu S, Hirashima Y, Morinaga R, Nishikawa K, Hisamatsu Y, Shimokata T, Inada-Inoue M, Shibata T, Takeuchi H, Watanabe T, Tokushige K, Maacke H, Shiaro K, Ando Y.
Watanabe K, et al. Among authors: shibata t.
Cancer Chemother Pharmacol. 2016 Jun;77(6):1157-64. doi: 10.1007/s00280-016-3019-5. Epub 2016 Apr 12.
Cancer Chemother Pharmacol. 2016.
PMID: 27071922
Clinical Trial.